Tezepelumab is an investigational, subcutaneously injected, human monoclonal antibody that inhibits thymic stromal lymphopoietin. It is proposed for treatment of patients with severe, uncontrolled asthma.

If you have a Hayes login, click here to view the full report on the Knowledge Center.